Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
TimesSquare Capital Management U.S. Small Cap Growth Strategy TimesSquare Capital Management, LLC | “Krystal Biotech Inc. is a biotechnology company developing and commercializing genetic medicines for patients with rare diseases. First quarter results missed the mark with declining levels of new patient starts and sales. While the quarterly results are disappointing, Vyjuvek is viewed as a durable and high-margin business. That therapy is a topical gel that promotes wound healing for patients with a rare and serious skin disorder called dystrophic epidermolysis. Krystal Biotech currently has seventeen sales reps and plans to add eight more. We reduced the position, which declined by -24% during the quarter. BSD Analysis: Krystal Biotech is a high-growth, specialized gene therapy pure-play whose stock is a conviction bet on the successful commercialization of Vyjuvek. The core thesis is driven by Vyjuvek's FDA approval for the treatment of Dystrophic Epidermolysis Bullosa (DEB), a severe genetic skin disease. This is a massive, high-value opportunity in a rare disease market, creating a near-monopoly. The company is rapidly scaling its commercial engine, with Q3 2025 Vyjuvek net product revenue hitting $100 million. The stock is a leveraged play on the successful launch execution and the advancement of its RED−D platform for generating new gene therapy candidates.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
